Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 847.0 g/mol |
|---|---|
| Molecular Formula | C46H62N4O11 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 5 |
| Exact Mass | 846.44150881 g/mol |
| Monoisotopic Mass | 846.44150881 g/mol |
| Topological Polar Surface Area | 206 A^2 |
| Heavy Atom Count | 61 |
| Formal Charge | 0 |
| Complexity | 1870 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Mycobutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 2 of 4 | |
|---|---|
| Drug Name | Rifabutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Lupin |
| 3 of 4 | |
|---|---|
| Drug Name | Rifabutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Lupin |
| 4 of 4 | |
|---|---|
| Drug Name | Mycobutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Lead Product(s): Rifabutin,Polymyxin B Sulfate,Meropenem
Therapeutic Area: Infections and Infectious Diseases Brand Name: BV100
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifabutin,Polymyxin B Sulfate,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 08, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the agreement aims to advance treatment for H. pylori infection.
Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Cumberland Pharmaceuticals
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Cumberland Pharmaceuticals
Deal Size : $4.0 million
Deal Type : Licensing Agreement
RedHill Secures $4M Investment, U.S. Co-Commercialization Deal for Talicia
Details : Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the agreement aims to advance treatment for H. pylori infection.
Product Name : Talicia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the focus is on addressing Helicobacter pylori (H. pylori) infection.
Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: $1.8 million Upfront Cash: $0.2 million
Deal Type: Licensing Agreement October 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.8 million
Deal Type : Licensing Agreement
RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia
Details : Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the focus is on addressing Helicobacter pylori (H. pylori) infection.
Product Name : Talicia
Product Type : Miscellaneous
Upfront Cash : $0.2 million
October 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
(MK-4646) is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): MK-4646,Rifabutin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MK-4646,Rifabutin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)
Details : (MK-4646) is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VH4524184 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.
Lead Product(s): VH4524184,Itraconazole,Rifabutin,Phenytoin,Metformin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VH4524184,Itraconazole,Rifabutin,Phenytoin,Metformin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of VH4524184 Tablet Absorption, Food Effect, & Drug Interaction in Healthy Adults
Details : VH4524184 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Product Name : Talicia
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin & clofazimine, It is designed to safely & effectively treat MAP+-related Crohn's disease.
Lead Product(s): Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Advances Crohn’s Program Following Positive RHB-104 Phase 3 Results
Details : RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin & clofazimine, It is designed to safely & effectively treat MAP+-related Crohn's disease.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 12, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.
Lead Product(s): Rifabutin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifabutin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioversys Completes BV100 Phase 2 for Ventilator-Associated Pneumonia
Details : BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.
Lead Product(s): Rifabutin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: GIBF2
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifabutin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : GIBF2
Deal Size : $6.0 million
Deal Type : Financing
Bioversys Secures Investment For BV100 Clinical Program in China
Details : The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Lead Product(s): Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Talicia® Launched in the United Arab Emirates
Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Product Name : Talicia
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
60
PharmaCompass offers a list of Rifabutin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rifabutin manufacturer or Rifabutin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifabutin manufacturer or Rifabutin supplier.
PharmaCompass also assists you with knowing the Rifabutin API Price utilized in the formulation of products. Rifabutin API Price is not always fixed or binding as the Rifabutin Price is obtained through a variety of data sources. The Rifabutin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Prestwick2_001109 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Prestwick2_001109, including repackagers and relabelers. The FDA regulates Prestwick2_001109 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Prestwick2_001109 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Prestwick2_001109 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Prestwick2_001109 supplier is an individual or a company that provides Prestwick2_001109 active pharmaceutical ingredient (API) or Prestwick2_001109 finished formulations upon request. The Prestwick2_001109 suppliers may include Prestwick2_001109 API manufacturers, exporters, distributors and traders.
click here to find a list of Prestwick2_001109 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Prestwick2_001109 DMF (Drug Master File) is a document detailing the whole manufacturing process of Prestwick2_001109 active pharmaceutical ingredient (API) in detail. Different forms of Prestwick2_001109 DMFs exist exist since differing nations have different regulations, such as Prestwick2_001109 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Prestwick2_001109 DMF submitted to regulatory agencies in the US is known as a USDMF. Prestwick2_001109 USDMF includes data on Prestwick2_001109's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Prestwick2_001109 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Prestwick2_001109 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Prestwick2_001109 Drug Master File in Korea (Prestwick2_001109 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Prestwick2_001109. The MFDS reviews the Prestwick2_001109 KDMF as part of the drug registration process and uses the information provided in the Prestwick2_001109 KDMF to evaluate the safety and efficacy of the drug.
After submitting a Prestwick2_001109 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Prestwick2_001109 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Prestwick2_001109 suppliers with KDMF on PharmaCompass.
A Prestwick2_001109 CEP of the European Pharmacopoeia monograph is often referred to as a Prestwick2_001109 Certificate of Suitability (COS). The purpose of a Prestwick2_001109 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Prestwick2_001109 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Prestwick2_001109 to their clients by showing that a Prestwick2_001109 CEP has been issued for it. The manufacturer submits a Prestwick2_001109 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Prestwick2_001109 CEP holder for the record. Additionally, the data presented in the Prestwick2_001109 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Prestwick2_001109 DMF.
A Prestwick2_001109 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Prestwick2_001109 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Prestwick2_001109 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Prestwick2_001109 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Prestwick2_001109 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Prestwick2_001109 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Prestwick2_001109 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Prestwick2_001109 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Prestwick2_001109 suppliers with NDC on PharmaCompass.
Prestwick2_001109 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Prestwick2_001109 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Prestwick2_001109 GMP manufacturer or Prestwick2_001109 GMP API supplier for your needs.
A Prestwick2_001109 CoA (Certificate of Analysis) is a formal document that attests to Prestwick2_001109's compliance with Prestwick2_001109 specifications and serves as a tool for batch-level quality control.
Prestwick2_001109 CoA mostly includes findings from lab analyses of a specific batch. For each Prestwick2_001109 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Prestwick2_001109 may be tested according to a variety of international standards, such as European Pharmacopoeia (Prestwick2_001109 EP), Prestwick2_001109 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Prestwick2_001109 USP).